<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173548</url>
  </required_header>
  <id_info>
    <org_study_id>HM20000118</org_study_id>
    <secondary_id>1R34HL118348-01A1</secondary_id>
    <nct_id>NCT02173548</nct_id>
  </id_info>
  <brief_title>Interleukin-1 Blockade in HF With Preserved EF</brief_title>
  <acronym>D-HART2</acronym>
  <official_title>Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure

        -  Standard treatment for heart failure, show less than ideal results in HFpEF

        -  Evidence of systemic inflammation is common in all forms of heart failure, including
           HFpEF

        -  The main hypothesis of this study is that systemic inflammation contributes to heart
           failure symptoms and exercise limitations in patients with HFpEF

        -  The main objective is to treat patients with HFpEF and evidence of systemic inflammation
           with an anti-inflammatory drug targeting Interleukin-1 (or placebo) to determine effects
           on cardiovascular function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure,
      characterized by symptoms of congestion and impaired exercise tolerance, secondary to
      impaired left ventricular filling (diastole) in absence of a significant impairment in
      contractility (LVEF&gt;50%) or significant valvular abnormalities, shunts or intra- or
      extra-cavitary obstruction.

      The standard treatment for patient with heart failure is very effective in Heart Failure with
      Reduced Ejection Fraction (HFrEF), but it not very effective in HFpEF.

      Evidence of systemic inflammation is common in all forms of heart failure, including HFpEF,
      and predicts worse outcomes. C reactive protein (CRP) is the preferred inflammatory biomarker
      used as risk predictor for cardiovascular disease. Patients with heart failure (HFpEF or
      HFrEF) with elevated CRP levels are more likely to be severely limited by heart failure
      symptoms, are more likely to be admitted to the hospital for heart failure, and are more
      likely to die of cardiac causes.

      Preclinical studies show that a key mediator of systemic inflammation, Interleukin-1 (IL-1),
      impairs cardiac and vascular function, and may contribute to the pathogenesis of heart
      failure.

      The main hypothesis of this study is that systemic inflammation, and IL-1 in particular,
      contributes to heart failure symptoms and exercise limitations in patients with HFpEF.

      The main objective is to treat patients with HFpEF and evidence of systemic inflammation with
      an IL-1 blocker, anakinra (recombinant human IL-1 receptor antagonist)(or placebo) to
      determine effects on exercise capacity measured as peak oxygen consumption at maximal
      cardiopulmonary exercise testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 11, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Aerobic Exercise Capacity</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Absolute changes in aerobic exercise capacity (peak VO2) after 12 weeks treatment. This will compare patients treated with anakinra and provide a randomized, double-blinded assessment of the effects of IL-1β blockade on aerobic exercise performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ventilatory Eefficiency</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Absolute changes in ventilatory efficiency (VE/VCO2 [carbon dioxide] slope) after 12 weeks treatment. This will compare patients treated with anakinra vs placebo, and provide a randomized, double-blinded assessment of the effects of IL-1β blockade on aerobic exercise performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Assessment of Diastolic and Systolic Function (Left Ventricular Ejection Fraction)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Structural and functional echocardiographic parameters include left and right ventricular dimensions, mass, systolic and diastolic function. (Change in e')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic and Contractile Reserve (e' Velocity and E/e' Ratio)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Exercise stress echocardiography will be performed at baseline and 12 weeks to measure diastolic and contractile reserve. We will perform an assessment before initiation of exercise and immediately after cessation of peak exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammation (C Reactive Protein Levels)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The change C reactive protein (CRP) levels will be reported at 12 weeks. Higher C reactive protein levels indicate greater inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Questionnaire-Minnesota Living With Heart Failure Questionnaire (MLWHF)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The Minnesota Living with Heart Failure questionnaire (MLWHF) is a 21-question graded questionnaire that has been extensively used to measure impairment in quality of life in patients with HF, with higher scores reflecting increased burden of HF symptoms. The questionnaire will be administered in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 105 with lower scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Questionnaire-Duke Activity Status Index (DASI)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Two independent questionnaires will be used to assess quality of life and HF symptoms. The Duke Activity Status Index (DASI) questionnaire is a 12-question, yes/no, instrument that allows for the calculation of perceived functional capacity, in which each question describes a different physical activity and the questions are weighted according to their degree of physical exertion. Higher scores indicate greater functional capacity. The questionnaire will be administered at 0, 4, 12 and 24 weeks in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 58.2 with higher scores indicating higher functional status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Admission for Acute Decompensated Heart Failure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants admitted to hospital for acute decompensated heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <arm_group_label>Anakinra</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptoms and signs of heart failure (NYHA II-III) and prior hospitalization for heart
             failure

          2. Recent Imaging Study (&lt;12 months) showing LVEF&gt;50% and Left Ventricular End Diastolic
             Volume Index (LVEDVI) &lt;97ml/m2

          3. Evidence of abnormal LV relaxation, filling, diastolic distensibility, and diastolic
             stiffness as shown by one of the following

             a. Invasive Hemodynamic measurements i. mean Pulmonary Capillary Wedge Pressure (mPCW)
             &gt;12 ii. Left Ventricular End Diastolic Pressure (LVEDP) &gt;16 mmHg b. Tissue Doppler
             Echocardiogram i. E/E' &gt;15 ii. E/E' 8-15 and one of the following: Left Ventricular
             Hypertrophy (LVH), Atrial fibrillation, Left Atrial Enlargement (LAE), E/A &lt;0.5 + DT
             (Deceleration Time) &gt;280, c. Biomarkers i. Brain Natriuretic Peptide (BNP) &gt;200pg/ml
             (not due to a concomitant disease such as pulmonary arterial hypertension, pulmonary
             embolism, acute renal failure, or other)

          4. CRP &gt; 2.0 mg/L

        Exclusion Criteria:

          -  Age &lt;21

          -  Concomitant conditions or treatments which would affect completion of the study or
             interpretation of the study tests including but not limited to the following
             conditions:

               -  physical inability to walk or run on a treadmill

               -  angina or evidence of spontaneous or inducible ischemia

               -  uncontrolled arterial hypertension

               -  atrial fibrillation (or other arrhythmias)

               -  moderate to severe valvular heart disease

               -  chronic pulmonary disease

               -  anemia (Hgb&lt;10 g/dl)

          -  Angina, uncontrolled hypertension or electrocardiograph (ECG) changes (i.e. ischemia,
             arrhythmias) that limit maximum exertion during cardiopulmonary exercise testing

          -  Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable
             cardioverter defibrillator (AICD) or coronary revascularization or cardiac surgery

          -  Active infection including chronic infection

          -  Active cancer (or prior diagnosis of cancer within the past 10 years)

          -  Recent (&lt;14 days) or active use of immunosuppressive drugs (including but not limited
             to high-dose corticosteroids [&gt;1_mg/kg of prednisone equivalent], Tumor Necrosis
             Factor (TNF)-α blockers, cyclosporine) not including Non-Steroidal Anti-Inflammatory
             Drugs (NSAIDs) or corticosteroids used for IV dye allergy only)

          -  Chronic auto-immune or auto-inflammatory disease (including but not limited to
             rheumatoid arthritis, systemic lupus erythematosus)

          -  Neutropenia (absolute neutrophil count&lt;1,800/mm3 [or &lt;1,000/mm3 in African-American
             patients])

          -  Severe impairment in renal function (estimated glomerular filtration rate &lt;30
             ml/kg*min)

          -  Recent or planned use of vaccination with live attenuated viruses

          -  Allergy to rubber or latex

          -  Allergy to products derived from Escherichia coli

          -  Pregnancy or breastfeeding

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Van Tassell, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>April 9, 2018</results_first_submitted>
  <results_first_submitted_qc>May 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2018</results_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>HFpEF</keyword>
  <keyword>diastole</keyword>
  <keyword>diastolic heart failure</keyword>
  <keyword>inflammation</keyword>
  <keyword>interleukin-1</keyword>
  <keyword>C-reactive protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02173548/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching Placebo
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching Placebo
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Aerobic Exercise Capacity</title>
        <description>Absolute changes in aerobic exercise capacity (peak VO2) after 12 weeks treatment. This will compare patients treated with anakinra and provide a randomized, double-blinded assessment of the effects of IL-1β blockade on aerobic exercise performance.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aerobic Exercise Capacity</title>
          <description>Absolute changes in aerobic exercise capacity (peak VO2) after 12 weeks treatment. This will compare patients treated with anakinra and provide a randomized, double-blinded assessment of the effects of IL-1β blockade on aerobic exercise performance.</description>
          <units>ml/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.9" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-1.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Ventilatory Eefficiency</title>
        <description>Absolute changes in ventilatory efficiency (VE/VCO2 [carbon dioxide] slope) after 12 weeks treatment. This will compare patients treated with anakinra vs placebo, and provide a randomized, double-blinded assessment of the effects of IL-1β blockade on aerobic exercise performance.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ventilatory Eefficiency</title>
          <description>Absolute changes in ventilatory efficiency (VE/VCO2 [carbon dioxide] slope) after 12 weeks treatment. This will compare patients treated with anakinra vs placebo, and provide a randomized, double-blinded assessment of the effects of IL-1β blockade on aerobic exercise performance.</description>
          <units>VE/VO2 slope</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-2.1" upper_limit="1.8"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-1.6" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Assessment of Diastolic and Systolic Function (Left Ventricular Ejection Fraction)</title>
        <description>Structural and functional echocardiographic parameters include left and right ventricular dimensions, mass, systolic and diastolic function. (Change in e')</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Assessment of Diastolic and Systolic Function (Left Ventricular Ejection Fraction)</title>
          <description>Structural and functional echocardiographic parameters include left and right ventricular dimensions, mass, systolic and diastolic function. (Change in e')</description>
          <units>cm/second</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.8" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="-0.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic and Contractile Reserve (e' Velocity and E/e' Ratio)</title>
        <description>Exercise stress echocardiography will be performed at baseline and 12 weeks to measure diastolic and contractile reserve. We will perform an assessment before initiation of exercise and immediately after cessation of peak exercise.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>Data not available for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic and Contractile Reserve (e' Velocity and E/e' Ratio)</title>
          <description>Exercise stress echocardiography will be performed at baseline and 12 weeks to measure diastolic and contractile reserve. We will perform an assessment before initiation of exercise and immediately after cessation of peak exercise.</description>
          <population>Data not available for all participants.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-5.7" upper_limit="3.1"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-4.5" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammation (C Reactive Protein Levels)</title>
        <description>The change C reactive protein (CRP) levels will be reported at 12 weeks. Higher C reactive protein levels indicate greater inflammation.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammation (C Reactive Protein Levels)</title>
          <description>The change C reactive protein (CRP) levels will be reported at 12 weeks. Higher C reactive protein levels indicate greater inflammation.</description>
          <units>mg/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-7.5" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-1.2" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Questionnaire-Minnesota Living With Heart Failure Questionnaire (MLWHF)</title>
        <description>The Minnesota Living with Heart Failure questionnaire (MLWHF) is a 21-question graded questionnaire that has been extensively used to measure impairment in quality of life in patients with HF, with higher scores reflecting increased burden of HF symptoms. The questionnaire will be administered in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 105 with lower scores indicating better quality of life.</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Questionnaire-Minnesota Living With Heart Failure Questionnaire (MLWHF)</title>
          <description>The Minnesota Living with Heart Failure questionnaire (MLWHF) is a 21-question graded questionnaire that has been extensively used to measure impairment in quality of life in patients with HF, with higher scores reflecting increased burden of HF symptoms. The questionnaire will be administered in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 105 with lower scores indicating better quality of life.</description>
          <units>units on MWLHF scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-19" upper_limit="1"/>
                    <measurement group_id="O2" value="-16" lower_limit="-24" upper_limit="-11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Questionnaire-Duke Activity Status Index (DASI)</title>
        <description>Two independent questionnaires will be used to assess quality of life and HF symptoms. The Duke Activity Status Index (DASI) questionnaire is a 12-question, yes/no, instrument that allows for the calculation of perceived functional capacity, in which each question describes a different physical activity and the questions are weighted according to their degree of physical exertion. Higher scores indicate greater functional capacity. The questionnaire will be administered at 0, 4, 12 and 24 weeks in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 58.2 with higher scores indicating higher functional status.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Questionnaire-Duke Activity Status Index (DASI)</title>
          <description>Two independent questionnaires will be used to assess quality of life and HF symptoms. The Duke Activity Status Index (DASI) questionnaire is a 12-question, yes/no, instrument that allows for the calculation of perceived functional capacity, in which each question describes a different physical activity and the questions are weighted according to their degree of physical exertion. Higher scores indicate greater functional capacity. The questionnaire will be administered at 0, 4, 12 and 24 weeks in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 58.2 with higher scores indicating higher functional status.</description>
          <units>units on DASI scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-2.5" upper_limit="12.6"/>
                    <measurement group_id="O2" value="6.5" lower_limit="-6.6" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Admission for Acute Decompensated Heart Failure</title>
        <description>Number of participants admitted to hospital for acute decompensated heart failure</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Admission for Acute Decompensated Heart Failure</title>
          <description>Number of participants admitted to hospital for acute decompensated heart failure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>One participant in the anakinra arm withdrew from the study before receiving any study-related interventions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg given subcutaneously once daily for 12 weeks
Anakinra</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching Placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute decompensated heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Non serious infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio Abbate, MD, PhD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>(804) 828-0513</phone>
      <email>antonio.abbate@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

